Development of radionuclides for innovative radiopharmaceuticals

grup photo

An important component of innovative radiopharmaceuticals, especially in oncology is the availability of alternative radionuclides with optimal decay properties, which allow to improve diagnostic or therapeutic efficiency. Currently a variety of accelerator, reactor (or Spallation Neutron Source) and generator produced radionuclides are developed and produced at PSI. Medical radionuclide must be available with high specific activity and purity. Here the choice of the nuclear reaction and subsequent radiochemical isolation strategy play a key role.

Localization and tracking of radio pharmaceuticals in vivo is performed by single photon emission computed tomography (SPECT) as well as by positron emission tomography (PET). The therapeutic radionuclides are particle emitters that are able to deposit a high quantity of energy in small volumes via a high "linear energy transfer" (LET). Here β-, α and also Auger electron emitters are used or considered to be useful for the therapeutic treatment.

The research group Radionuclide Development is a joint research group of the Laboratory of Radiochemistry and of the Center of Radiopharmaceutical Sciences at PSI. 

 

  • Borgna F, Haller S, Monné Rodriguez JM, Ginj M, Grundler PV, Zeevaart JR, et al.
    Combination of terbium-161 with somatostatin receptor antagonists - a potential paradigm shift for the treatment of neuroendocrine neoplasms
    European Journal of Nuclear Medicine and Molecular Imaging. 2022; 49: 1113-1126. https://doi.org/10.1007/s00259-021-05564-0
    DORA PSI
  • Braccini S, Carzaniga TS, Dellepiane G, Grundler PV, Scampoli P, van der Meulen NP, et al.
    Optimization of 68Ga production at an 18 MeV medical cyclotron with solid targets by means of cross-section measurement of 66Ga, 67Ga and 68Ga
    Applied Radiation and Isotopes. 2022; 186: 110252 (9 pp.). https://doi.org/10.1016/j.apradiso.2022.110252
    DORA PSI
  • Dellepiane G, Casolaro P, Favaretto C, Grundler PV, Mateu I, Scampoli P, et al.
    Cross section measurement of terbium radioisotopes for an optimized 155Tb production with an 18 MeV medical PET cyclotron
    Applied Radiation and Isotopes. 2022; 184: 110175 (14 pp.). https://doi.org/10.1016/j.apradiso.2022.110175
    DORA PSI
  • Durán MT, Juget F, Nedjadi Y, Bailat C, Grundler PV, Talip Z, et al.
    Half-life measurement of 44Sc and 44mSc
    Applied Radiation and Isotopes. 2022; 190: 110507 (10 pp.). https://doi.org/10.1016/j.apradiso.2022.110507
    DORA PSI
  • Eichler R, Kiselev D, Koschik A, Knecht A, van der Meulen N, Scheibl R, et al.
    IMPACT conceptual design report
    Villigen PSI: Paul Scherrer Institut; 2022. PSI Bericht: 22-01.
    DORA PSI
  • Hemmingsson J, Svensson J, van der Meulen NP, Müller C, Bernhardt P
    Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90
    EJNMMI Physics. 2022; 9(1): 65 (13 pp.). https://doi.org/10.1186/s40658-022-00495-7
    DORA PSI
  • Juget F, Talip Z, Nedjadi Y, Durán MT, Grundler PV, Zeevaart JR, et al.
    Precise activity measurements of medical radionuclides using an ionization chamber: a case study with Terbium-161
    EJNMMI Physics. 2022; 9(1): 19 (18 pp.). https://doi.org/10.1186/s40658-022-00448-0
    DORA PSI
  • Tosato M, Verona M, Favaretto C, Pometti M, Zanoni G, Scopelliti F, et al.
    Chelation of theranostic copper radioisotopes with S-rich macrocycles: from radiolabelling of copper-64 to in vivo investigation
    Molecules. 2022; 27(13): 4158 (19 pp.). https://doi.org/10.3390/molecules27134158
    DORA PSI
  • Alves F, Antunes IF, Cazzola E, Cleeren F, Cornelissen B, Denkova A, et al.
    Highlight selection of radiochemistry and radiopharmacy developments by editorial board
    EJNMMI Radiopharmacy and Chemistry. 2021; 6(1): 31 (16 pp.). https://doi.org/10.1186/s41181-021-00146-9
    DORA PSI
  • Baum RP, Singh A, Kulkarni HR, Bernhardt P, Rydén T, Schuchardt C, et al.
    First-in-human application of terbium-161: a feasibility study using 161Tb-DOTATOC
    Journal of Nuclear Medicine. 2021; 62(10): 1391-1397. https://doi.org/10.2967/jnumed.120.258376
    DORA PSI
  • Bernhardt P, Svensson J, Hemmingsson J, van der Meulen NP, Zeevaart JR, Konijnenberg MW, et al.
    Dosimetric analysis of the short-ranged particle emitter 161Tb for radionuclide therapy of metastatic prostate cancer
    Cancers. 2021; 13(9): 2011 (13 pp.). https://doi.org/10.3390/cancers13092011
    DORA PSI
  • Borgna F, Barritt P, Grundler PV, Talip Z, Cohrs S, Zeevaart JR, et al.
    Simultaneous visualization of 161Tb-and 177Lu-labeled somatostatin analogues using dual-isotope SPECT imaging
    Pharmaceutics. 2021; 13(4): 536 (13 pp.). https://doi.org/10.3390/pharmaceutics13040536
    DORA PSI
  • Duchemin C, Ramos JP, Stora T, Ahmed E, Aubert E, Audouin N, et al.
    CERN-MEDICIS: a review since commissioning in 2017
    Frontiers in Medicine. 2021; 8: 693682 (11 pp.). https://doi.org/10.3389/fmed.2021.693682
    DORA PSI
  • Durán MT, Juget F, Nedjadi Y, Bochud F, Talip Z, van der Meulen NP, et al.
    Ytterbium-175 half-life determination
    Applied Radiation and Isotopes. 2021; 176: 109893 (8 pp.). https://doi.org/10.1016/j.apradiso.2021.109893
    DORA PSI
  • Favaretto C, Talip Z, Borgna F, Grundler PV, Dellepiane G, Sommerhalder A, et al.
    Cyclotron production and radiochemical purification of terbium-155 for SPECT imaging
    EJNMMI Radiopharmacy and Chemistry. 2021; 6: 37 (17 pp.). https://doi.org/10.1186/s41181-021-00153-w
    DORA PSI
  • Heinke R, Chevallay E, Chrysalidis K, Cocolios TE, Duchemin C, Fedosseev VN, et al.
    Efficient production of high specific activity thulium-167 at Paul Scherrer Institute and CERN-MEDICIS
    Frontiers in Medicine. 2021; 8: 712374 (17 pp.). https://doi.org/10.3389/fmed.2021.712374
    DORA PSI
  • Juget F, Talip Z, Buchillier T, Durán MT, Nedjadi Y, Desorgher L, et al.
    Determination of the gamma and X-ray emission intensities of terbium-161
    Applied Radiation and Isotopes. 2021; 174: 109770 (6 pp.). https://doi.org/10.1016/j.apradiso.2021.109770
    DORA PSI
  • Lima TVM, Gnesin S, Strobel K, del Sol Pérez M, Roos JE, Müller C, et al.
    Fifty shades of scandium: comparative study of PET capabilities using Sc-43 and Sc-44 with respect to conventional clinical radionuclides
    Diagnostics. 2021; 11(10): 1826 (11 pp.). https://doi.org/10.3390/diagnostics11101826
    DORA PSI
  • Müller C, Schibli R, Bernhardt P, Köster U, van der Meulen NP
    Terbium radionuclides for theranostics
    In: Caplan MJ, ed. Reference module in biomedical sciences. sine loco: Elsevier; 2021:(12 pp.). https://doi.org/10.1016/B978-0-12-822960-6.00076-4
    DORA PSI
  • Steyn GF, van der Walt TN, Szelecsényi F, Perrang C, Brümmer JW, Vermeulen C, et al.
    Large-scale production of 88Y and 88Zr/88Y generators: a proof of concept study for a 70 MeV H- cyclotron
    Applied Radiation and Isotopes. 2021; 168: 109469 (11 pp.). https://doi.org/10.1016/j.apradiso.2020.109469
    DORA PSI
  • Taddio MF, Castro Jaramillo CA, Runge P, Blanc A, Keller C, Talip Z, et al.
    In vivo imaging of local inflammation: monitoring LPS-induced CD80/CD86 upregulation by PET
    Molecular Imaging and Biology. 2021; 23: 196-207. https://doi.org/10.1007/s11307-020-01543-3
    DORA PSI
  • Talip Z, Juget F, Ulrich J, Nedjadi Y, Buchillier T, Durán MT, et al.
    Determination of the gamma and X-ray emission intensities of erbium-169
    Applied Radiation and Isotopes. 2021; 176: 109823 (9 pp.). https://doi.org/10.1016/j.apradiso.2021.109823
    DORA PSI
  • Talip Z, Borgna F, Müller C, Ulrich J, Duchemin C, Ramos JP, et al.
    Production of mass-separated erbium-169 towards the first preclinical in vitro investigations
    Frontiers in Medicine. 2021; 8: 643175 (11 pp.). https://doi.org/10.3389/fmed.2021.643175
    DORA PSI
  • van der Meulen NP, Strobel K, Lima TVM
    New radionuclides and technological advances in SPECT and PET scanners
    Cancers. 2021; 13(24): 6183 (15 pp.). https://doi.org/10.3390/cancers13246183
    DORA PSI
  • van der Meulen NP, Talip Z
    Non-conventional radionuclides: the pursuit for perfection
    In: Caplan MJ, ed. Reference module in biomedical sciences. sine loco: Elsevier; 2021:(10 pp.). https://doi.org/10.1016/B978-0-12-822960-6.00052-1
    DORA PSI
  • Durán MT, Juget F, Nedjadi Y, Bochud F, Grundler PV, Gracheva N, et al.
    Determination of 161Tb half-life by three measurement methods
    Applied Radiation and Isotopes. 2020; 159: 109085 (9 pp.). https://doi.org/10.1016/j.apradiso.2020.109085
    DORA PSI
  • Gracheva N, Carzaniga TS, Schibli R, Braccini S, van der Meulen NP
    165Er: a new candidate for Auger electron therapy and its possible cyclotron production from natural holmium targets
    Applied Radiation and Isotopes. 2020; 159: 109079 (8 pp.). https://doi.org/10.1016/j.apradiso.2020.109079
    DORA PSI
  • Grundler PV, Eichler R, Talip Z, Schubiger PA, Schibli R, van der Meulen NP
    The metamorphosis of radionuclide production and development at Paul Scherrer Institute
    Chimia. 2020; 74(12): 968-975. https://doi.org/10.2533/CHIMIA.2020.968
    DORA PSI
  • Lima TVM, Gnesin S, Nitzsche E, Ortega PG, Müller C, van der Meulen NP
    First phantom-based quantitative assessment of scandium-44 using a commercial PET device
    Frontiers in Physics. 2020; 8: 241 (10 pp.). https://doi.org/10.3389/fphy.2020.00241
    DORA PSI
  • Marin I, Rydèn T, Van Essen M, Svensson J, Gracheva N, Köster U, et al.
    Establishment of a clinical SPECT/CT protocol for imaging of 161Tb
    EJNMMI Physics. 2020; 7(1): 45 (16 pp.). https://doi.org/10.1186/s40658-020-00314-x
    DORA PSI
  • Müller C, Béhé M, Geistlich S, van der Meulen NP, Schibli R
    Targeted radiotherapeutics from 'bench-to-bedside'
    Chimia. 2020; 74(12): 939-945. https://doi.org/10.2533/CHIMIA.2020.939
    DORA PSI
  • Nedjadi Y, Juget F, Desorgher L, Durán MT, Bochud F, Müller C, et al.
    Activity standardisation of 161Tb
    Applied Radiation and Isotopes. 2020; 166: 109411 (13 pp.). https://doi.org/10.1016/j.apradiso.2020.109411
    DORA PSI
  • Nizou G, Favaretto C, Borgna F, Grundler PV, Saffon-Merceron N, Platas-Iglesias C, et al.
    Expanding the scope of pyclen-picolinate lanthanide chelates to potential theranostic applications
    Inorganic Chemistry. 2020; 59(16): 11736-11748. https://doi.org/10.1021/acs.inorgchem.0c01664
    DORA PSI
  • Talip Z, Favaretto C, Geistlich S, van der Meulen NP
    A step-by-step guide for the novel radiometal production for medical applications: case studies with 68Ga, 44Sc, 177Lu and 161Tb
    Molecules. 2020; 25(4): 966 (29 pp.). https://doi.org/10.3390/molecules25040966
    DORA PSI
  • Zhang H, Eichler R, Grillenberger J, Hirzel W, Joray S, Kiselev DC, et al.
    BDSIM simulation of the complete radionuclide production beam line from beam splitter to target station at the PSI cyclotron facility
    In: Conradie L, Garrett De Villiers J, Schaa VRW, eds. CYC2019. 22nd international conference on cyclotrons and their applications. Vol. 22. International conference on cyclotrons and their applications. Geneva: JACoW Publishing; 2020:275-278. https://doi.org/10.18429/JACoW-Cyclotrons2019-WEB04
    DORA PSI
  • van Heerden MR, Cole K, van der Meulen NP, Franzidis J-P, Buffler A
    Extending the life of SnO268Ge/68Ga generators used in the radiolabelling of ion exchange resins
    Applied Radiation and Isotopes. 2020; 158: 109044 (6 pp.). https://doi.org/10.1016/j.apradiso.2020.109044
    DORA PSI
  • van der Meulen NP, Hasler R, Talip Z, Grundler PV, Favaretto C, Umbricht CA, et al.
    Developments toward the implementation of 44Sc production at a medical cyclotron
    Molecules. 2020; 25(20): 4706 (16 pp.). https://doi.org/10.3390/molecules25204706
    DORA PSI
  • van der Meulen NP, Eichler R, Grundler PV, Hasler R, Hirzel W, Joray S, et al.
    The use of PSI's IP2 beam line towards exotic radionuclide development and its application towards proof-of-preclnical and clinical studies
    In: Conradie L, Garrett De Villiers J, Schaa VRW, eds. CYC2019. 22nd international conference on cyclotrons and their applications. Vol. 22. International conference on cyclotrons and their applications. Geneva: JACoW Publishing; 2020:132-135. https://doi.org/10.18429/JACoW-Cyclotrons2019-TUA03
    DORA PSI
  • Carzaniga TS, van der Meulen NP, Hasler R, Kottler C, Peier P, Türler A, et al.
    Measurement of the 43Sc production cross-section with a deuteron beam
    Applied Radiation and Isotopes. 2019; 145: 205-208. https://doi.org/10.1016/j.apradiso.2018.12.031
    DORA PSI
  • Cicone F, Gnesin S, Denoël T, Stora T, van der Meulen NP, Müller C, et al.
    Internal radiation dosimetry of a 152Tb-labeled antibody in tumor-bearing mice
    EJNMMI Research. 2019; 9: 53 (10 pp.). https://doi.org/10.1186/s13550-019-0524-7
    DORA PSI
  • Gracheva N, Müller C, Talip Z, Heinitz S, Köster U, Zeevaart JR, et al.
    Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy
    EJNMMI Radiopharmacy and Chemistry. 2019; 4: 12 (16 pp.). https://doi.org/10.1186/s41181-019-0063-6
    DORA PSI
  • Mikolajczak R, van der Meulen NP, Lapi SE
    Radiometals for imaging and theranostics, current production, and future perspectives
    Journal of Labelled Compounds and Radiopharmaceuticals. 2019; 62(10): 615-634. https://doi.org/10.1002/jlcr.3770
    DORA PSI
  • Müller C, De Prado Leal M, Dominietto MD, Umbricht CA, Safai S, Perrin RL, et al.
    Combination of proton therapy and radionuclide therapy in mice: preclinical pilot sudy at the Paul Scherrer Institute
    Pharmaceutics. 2019; 11(9): 450 (13 pp.). https://doi.org/10.3390/pharmaceutics11090450
    DORA PSI
  • Müller C, Singh A, Umbricht CA, Kulkarni HR, Johnston K, Benešová M, et al.
    Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer
    EJNMMI Research. 2019; 9(1): 68 (10 pp.). https://doi.org/10.1186/s13550-019-0538-1
    DORA PSI
  • Müller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, et al.
    Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
    European Journal of Nuclear Medicine and Molecular Imaging. 2019; 46(9): 1919-1930. https://doi.org/10.1007/s00259-019-04345-0
    DORA PSI
  • Pretze M, van der Meulen N P, Wängler C, Schibli R, Wängler B
    Targeted 64Cu-labeled gold nanoparticles for dual imaging with positron emission tomography and optical imaging
    Journal of Labelled Compounds and Radiopharmaceuticals. 2019; 62(8): 471-482. https://doi.org/10.1002/jlcr.3736
    DORA PSI
  • Siwowska K, Guzik P, Domnanich KA, Monné Rodríguez JM, Bernhardt P, Ponsard B, et al.
    Therapeutic potential of 47Sc in comparison to 177Lu and 90Y: preclinical investigations
    Pharmaceutics. 2019; 11(8): 424 (13 pp.). https://doi.org/10.3390/pharmaceutics11080424
    DORA PSI
  • Umbricht CA, Köster U, Bernhardt P, Gracheva N, Johnston K, Schibli R, et al.
    Alpha-PET for prostate cancer: preclinical investigation using 149Tb-PSMA-617
    Scientific Reports. 2019; 9: 17800 (10 pp.). https://doi.org/10.1038/s41598-019-54150-w
    DORA PSI
  • Zhang J, Singh A, Kulkarni HR, Schuchardt C, Müller D, Wester H-J, et al.
    From bench to bedside—the Bad Berka experience with first-in-human studies
    Seminars in Nuclear Medicine. 2019; 49(5): 422-437. https://doi.org/10.1053/j.semnuclmed.2019.06.002
    DORA PSI
  • van der Meulen NP, Hasler R, Blanc A, Farkas R, Benešová M, Talip Z, et al.
    Implementation of a new separation method to produce qualitatively improved 64Cu
    Journal of Labelled Compounds and Radiopharmaceuticals. 2019; 62(8): 460-470. https://doi.org/10.1002/jlcr.3730
    DORA PSI
  • Gerchow L, Braccini S, Carzaniga T, Cooke D, Döbeli M, Kirch K, et al.
    High efficiency cyclotron trap assisted positron moderator
    Instruments. 2018; 2(3): 10 (10 pp.). https://doi.org/10.3390/instruments2030010
    DORA PSI
  • Müller C, Domnanich KA, Umbricht CA, van der Meulen NP
    Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application
    British Journal of Radiology. 2018; 91(1091): 20180074 (13 pp.). https://doi.org/10.1259/bjr.20180074
    DORA PSI
  • Schniering J, Borgna F, Siwowska K, Benešová M, Cohrs S, Hasler R, et al.
    In vivo labeling of plasma proteins for imaging of enhanced vascular permeability in the lungs
    Molecular Pharmaceutics. 2018; 15(11): 4995-5004. https://doi.org/10.1021/acs.molpharmaceut.8b00606
    DORA PSI
  • Umbricht CA, Benešová M, Hasler R, Schibli R, van der Meulen NP, Müller C
    Design and preclinical evaluation of an albumin-binding PSMA ligand for 64Cu-based PET imaging
    Molecular Pharmaceutics. 2018; 15(12): 5556-5564. https://doi.org/10.1021/acs.molpharmaceut.8b00712
    DORA PSI
  • Baum RP, Singh A, Benešová M, Vermeulen C, Gnesin S, Köster U, et al.
    Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152Tb-DOTATOC
    Dalton Transactions. 2017; 46(42): 14638-14646. https://doi.org/10.1039/c7dt01936j
    DORA PSI
  • Carzaniga TS, Auger M, Braccini S, Bunka M, Ereditato A, Nesteruk KP, et al.
    Measurement of 43Sc and 44Sc production cross-section with an 18 MeV medical PET cyclotron
    Applied Radiation and Isotopes. 2017; 129: 96-102. https://doi.org/10.1016/j.apradiso.2017.08.013
    DORA PSI
  • Dolley SG, Steyn GF, van Rooyen TJ, Szelecsényi F, Kovács Z, Vermeulen C, et al.
    Concurrent spectrometry of annihilation radiation and characteristic gamma-rays for activity assessment of selected positron emitters
    Applied Radiation and Isotopes. 2017; 129: 76-86. https://doi.org/10.1016/j.apradiso.2017.07.057
    DORA PSI
  • Domnanich KA, Müller C, Benešová M, Dressler R, Haller S, Köster U, et al.
    47Sc as useful β–-emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes
    EJNMMI Radiopharmacy and Chemistry. 2017; 2: 5 (17 pp.). https://doi.org/10.1186/s41181-017-0024-x
    DORA PSI
  • Domnanich KA, Eichler R, Müller C, Jordi S, Yakusheva V, Braccini S, et al.
    Production and separation of 43Sc for radiopharmaceutical purposes
    EJNMMI Radiopharmacy and Chemistry. 2017; 2: 14 (17 pp.). https://doi.org/10.1186/s41181-017-0033-9
    DORA PSI
  • Honarvar H, Müller C, Cohrs S, Haller S, Westerlund K, Eriksson Karlström A, et al.
    Evaluation of the first 44Sc-labeled Affibody molecule for imaging of HER2-expressing tumors
    Nuclear Medicine and Biology. 2017; 45: 15-21. https://doi.org/10.1016/j.nucmedbio.2016.10.004
    DORA PSI
  • Müller C, van der Meulen NP, Benešová M, Schibli R
    Therapeutic radiometals beyond 177Lu and 90Y: production and application of promising α-particle, β–-particle, and Auger electron emitters
    Journal of Nuclear Medicine. 2017; 58(Suppl. 2): 91S-96S. https://doi.org/10.2967/jnumed.116.186825
    DORA PSI
  • Singh A, van der Meulen NP, Müller C, Klette I, Kulkarni HR, Türler A, et al.
    First-in-human PET/CT imaging of metastatic neuroendocrine neoplasms with cyclotron-produced 44Sc-DOTATOC: a proof-of-concept study
    Cancer Biotherapy and Radiopharmaceuticals. 2017; 32(4): 124-132. https://doi.org/10.1089/cbr.2016.2173
    DORA PSI
  • Steyn GF, Dolley SG, Szelecsényi F, Kovács Z, van der Meulen NP, Vermeulen C
    In-flight annihilation correction for 511 keV photon spectrometry
    In: Plompen A, Hambsch F-J, Schillebeeckx P, Mondelaers W, Kopecky S, Siegler P, et al., eds. ND 2016: international conference on nuclear data for science and technology. Vol. 146. EPJ web of conferences. sine loco: EDP Sciences; 2017:08010 (4 pp.). https://doi.org/10.1051/epjconf/201714608010
    DORA PSI
  • Umbricht CA, Benešová M, Schmid RM, Türler A, Schibli R, van der Meulen NP, et al.
    44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
    EJNMMI Research. 2017; 7(1): 9 (10 pp.). https://doi.org/10.1186/s13550-017-0257-4
    DORA PSI
  • Bunka M, Müller C, Vermeulen C, Haller S, Türler A, Schibli R, et al.
    Imaging quality of 44Sc in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PET
    Applied Radiation and Isotopes. 2016; 110: 129-133. https://doi.org/10.1016/j.apradiso.2016.01.006
    DORA PSI
  • Domnanich K, Müller C, Farkas R, Schmid RM, Ponsard B, Schibli R, et al.
    44Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations
    EJNMMI Radiopharmacy and Chemistry. 2016; 1: 8 (19 pp.). https://doi.org/10.1186/s41181-016-0013-5
    DORA PSI
  • Farkas R, Siwowska K, Ametamey SM, Schibli R, van der Meulen NP, Müller C
    64Cu- and 68Ga-based PET imaging of folate receptor-positive tumors: development and evaluation of an albumin-binding NODAGA−folate
    Molecular Pharmaceutics. 2016; 13(6): 1979-1987. https://doi.org/10.1021/acs.molpharmaceut.6b00143
    DORA PSI
  • Haller S, Pellegrini G, Vermeulen C, van der Meulen NP, Köster U, Bernhardt P, et al.
    Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of 161Tb-folate and 177Lu-folate
    EJNMMI Research. 2016; 6(1): 13 (11 pp.). https://doi.org/10.1186/s13550-016-0171-1
    DORA PSI
  • Müller C, Vermeulen C, Köster U, Johnston K, Türler A, Schibli R, et al.
    Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics
    EJNMMI Radiopharmacy and Chemistry. 2016; 1(1): 5 (5 pp.). https://doi.org/10.1186/s41181-016-0008-2
    DORA PSI
  • Müller C, Vermeulen C, Johnston K, Köster U, Schmid R, Türler A, et al.
    Preclinical in vivo application of 152Tb-DOTANOC: a radiolanthanide for PET imaging
    EJNMMI Research. 2016; 6: 35 (10 pp.). https://doi.org/10.1186/s13550-016-0189-4
    DORA PSI
  • van der Meulen NP, Steyn GF, Vermeulen C, van Rooyen TJ
    Production of 28Mg by bombardment of natCl with 200 MeV protons: proof-of-concept study for a stacked LiCl target
    Applied Radiation and Isotopes. 2016; 115: 125-132. https://doi.org/10.1016/j.apradiso.2016.04.026
    DORA PSI
  • van der Meulen NP, Bunka M, Domnanich K, Müller C, Haller S, Vermeulen C, et al.
    Cyclotron production of 44Sc: from bench to bedside
    Nuclear Medicine and Biology. 2015; 42(9): 745-751. https://doi.org/10.1016/j.nucmedbio.2015.05.005
    DORA PSI
  • Müller C, Fischer E, Behe M, Köster U, Dorrer H, Reber J, et al.
    Future prospects for SPECT imaging using the radiolanthanide terbium-155 — production and preclinical evaluation in tumor-bearing mice
    Nuclear Medicine and Biology. 2014; 41(S): e58-e65. https://doi.org/10.1016/j.nucmedbio.2013.11.002
    DORA PSI
  • Müller C, Bunka M, Haller S, Köster U, Groehn V, Bernhardt P, et al.
    Promising prospects for 44Sc-/47Sc-based theragnostics: application of 47Sc for radionuclide tumor therapy in mice
    Journal of Nuclear Medicine. 2014; 55(10): 1658-1664. https://doi.org/10.2967/jnumed.114.141614
    DORA PSI
  • Steyn GF, Vermeulen C, Szelecsényi F, Kovács Z, Hohn A, van der Meulen NP, et al.
    Cross sections of proton-induced reactions on 152Gd, 155Gd and 159Tb with emphasis on the production of selected Tb radionuclides
    Nuclear Instruments and Methods in Physics Research, Section B: Beam Interactions with Materials and Atoms. 2014; 319: 128-140. https://doi.org/10.1016/j.nimb.2013.11.013
    DORA PSI

Further Information

Contact

Paul Scherrer Institut
Laboratory of Radiochemistry
Secretariate
OFLB/108

Forschungsstrasse 111
5232 Villigen PSI
Switzerland

Mrs. A. Blattmann
+41 56 310 2401
angela.blattmann@psi.ch

Directions to PSI

How to get to the Paul Scherrer Institute (description and map)

LRC Annual Reports

The Annual Reports of the LRC contain accounts of ongoing scientific research and provide an overview of the variety of topics investigated in our laboratory. Until 2015, they comprise results achieved within the former Laboratory for Radio- and Environmental Chemistry (LCH).